-transparent.png){kind=logo}
Bismuth concentration was measured in plasma, dried leucocytes and urine in nine patients before, during and after treatment with tripotassium dicitrato bismuthate (De-Noltab 2 b.d.) for 6 weeks. During treatment there was an 8.5-fold rise in median plasma bismuth concentration (P less than 0.01), a non-significant doubling of leucocyte bismuth content, and a 349-fold rise in 24-h urinary bismuth excretion (P less than 0.01). The significantly increased urinary bismuth excretion continued for at least 3 months after cessation of treatment with tripotassium dicitrato bismuthate, indicating accumulation of bismuth during treatment with this drug.
Related Publications
C J Gavey, and
M L Szeto, and
C U Nwokolo, and
J Sercombe, and
R E Pounder
February 1989,
Alimentary pharmacology & therapeutics,
C J Gavey, and
M L Szeto, and
C U Nwokolo, and
J Sercombe, and
R E Pounder
May 1994,
Clinical pharmacology and therapeutics,
C J Gavey, and
M L Szeto, and
C U Nwokolo, and
J Sercombe, and
R E Pounder
January 1989,
European journal of clinical pharmacology,
C J Gavey, and
M L Szeto, and
C U Nwokolo, and
J Sercombe, and
R E Pounder
December 1990,
Alimentary pharmacology & therapeutics,
C J Gavey, and
M L Szeto, and
C U Nwokolo, and
J Sercombe, and
R E Pounder
April 1992,
Alimentary pharmacology & therapeutics,
C J Gavey, and
M L Szeto, and
C U Nwokolo, and
J Sercombe, and
R E Pounder
April 1988,
Gut,
C J Gavey, and
M L Szeto, and
C U Nwokolo, and
J Sercombe, and
R E Pounder
October 1990,
British journal of clinical pharmacology,
C J Gavey, and
M L Szeto, and
C U Nwokolo, and
J Sercombe, and
R E Pounder
October 1991,
Alimentary pharmacology & therapeutics,
C J Gavey, and
M L Szeto, and
C U Nwokolo, and
J Sercombe, and
R E Pounder
January 1986,
Postgraduate medical journal,
C J Gavey, and
M L Szeto, and
C U Nwokolo, and
J Sercombe, and
R E Pounder
August 1989,
Alimentary pharmacology & therapeutics,
